Drug Profile
Research programme: RNA inhibitors - Novo Nordisk/Roche
Alternative Names: LNA-antimicroRNA-155; LNA-antimiR-155Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Santaris Pharma
- Developer Novo Nordisk; Roche
- Class Antisense oligonucleotides
- Mechanism of Action MicroRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Denmark